| Prev Close | 45.48 |
| Day Low/High | 45.27 / 45.85 |
| 52 Wk Low/High | 40.01 / 63.86 |
Perrigo Co. Plc (PRGO)
45.62
NYSE
| Exchange | NYSE |
| Shares Outstanding | 136.48B |
| Market Cap | 6.21B |
| P/E Ratio | 26.38 |
| Div & Yield | N.A. (N.A) |
Stressed Out: Valeant Shareholders Flee on McKesson Warning
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
Stressed Out: Free Cash Flow Is All That Counts Now for Valeant
With a $31 billion debt load, the drugmaker has to show it has the firepower needed to fend off creditors.
Stocks to Worry the Bullish Cabal
Here are some high-profile and widely-held stocks whose charts should concern the bullish cabal: Netflix Starbucks Disney Tesla Coca-Cola Prudential Ford Valeant Perrigo Dollar Tree Macy's Nike Note: These stocks represent a broad swath of secto...
Midday Report: American Airlines Falls on Weak August Traffic; U.S. Stocks Climb
Stocks climbed, though worries over how soon the Federal Reserve might hike interest rates kept markets wary.
Perrigo Shares Climb on Starboard Value Investment
The activist fund says Perrigo's promises over the past year have been "woefully unfulfilled."
Morning Movers: PRGO, MYL, HPQ, MRO, RIG
Falling crude oil prices continued to weigh on markets Monday.
Closing Bell: Perrigo Cuts Full-Year Guidance; U.S. Stocks Slip
U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.
Trending Tickers: RL, RAD, RIG, PRGO, KLAC
Ralph Lauren shares surge on earnings beat amid lethargic market action.
Jim Cramer: Perrigo is Problematic
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
Why I Feel Bearish About the Market
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
Don't 'Catch a Falling Knife' with Perrigo
The stock's tumbling to near a 52-week low, but charts suggest caution.
Valeant Shares Rally on Outlook, but Analysts Say Debt Worries Still Loom
Analysts say Tuesday's earnings beat could spell trouble in terms of coping with its $31 billion worth of debt.
Looking for Relief From Biotech Pain
A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.
Valeant, Walgreens CEOs to Tackle 'Speed Bumps'
Papa is set to meet with Walgreens management in hopes of ironing out "speed bumps."
Endo Could Be the Next Activist Target in Generics
Problems with mesh products and high leverage might scare away a potential buyer.
Takeaways and Observations
I was out of the office yesterday, but my take on the session is: "Up, Down, Up, Flat." It was a mixed day in terms of economic data, with potholes everywhere. (You'd have to be blind not to see them.) It was all about retail yet again, and it sure ...
Valeant Whipsawed by Criticism Over Drug Prices and New Leadership
The drugmaker's quest to rebrand itself as a patient-first company is foundering over renewed controversy over drug pricing.
Teva Should Break Out of Droopy Drug Pack
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
My Takeaways and Observations
Did I mention that the market has no memory from day to day? It was a busy short-side day for me today. Disney (DIS) -- why the mouse is no longing roaring. On management B.S. Macy's (M). Sears (SHLD) is the elephant in the room and a possible ...
There's a Lot to Be Resolved on Perrigo
It reports tomorrow, but where will the company ultimately fall this quarter?
Papa and His Brand New Gig (at VRX)
"Papa's in the swing. He ain't too hip about that new breed babe. He ain't no drag. Papa's got a brand new bag." -- James Brown, Papa's Got a Brand New Bag Jim "El Capitan" Cramer clearly outlined the key risks facing Valeant Pharmaceuticals (VRX) t...
Cramer: The World Is Gunning for Valeant
And Joe Papa can't stop the world.
Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job
Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.
Cramer on Valeant’s New CEO Joseph Papa
New Valeant CEO and former Perrigo CEO Joseph Papa will be joining TheStreet's Jim Cramer on "Mad Money" tonight.
Perrigo Bears Turn Aggressive
Perrigo could have an oversold bounce at any time as bears turn aggressive, but nothing right now indicates a price bottom.
Avoid Valeant (Redux)
I noted in my previous missive that my ursine friend Jim Chanos spoke out on CNBC's Fast Money Halftime show today in favor of shorting the Chinese stock market. Well, he also just expressed skepticism on Valeant Pharmaceuticals (VRX) -- another vie...
My Diagnosis of Valeant Pharmaceuticals
"Valeant, of course, was a sewer ... [and its directors deserve] all the opprobrium they are getting." -- Charlie Munger, vice chairman of Berkshire Hathaway (BRK.A, BRK.B), at this weekend's annual Berkshire shareholder meeting Pershing Square's Bi...
It's Scary Down There: Buying at the Lows
Get paid very well for making the 'uncomfortable' play others are afraid to take.
It's Scary Down There: Buying at the Lows
Get paid very well for making the 'uncomfortable' play others are afraid to take.
